Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 239

1.

N2 lung cancer is not all the same: an analysis of different prognostic groups.

Bertoglio P, Ricciardi S, Alì G, Aprile V, Korasidis S, Palmiero G, Fontanini G, Mussi A, Lucchi M.

Interact Cardiovasc Thorac Surg. 2018 May 19. doi: 10.1093/icvts/ivy171. [Epub ahead of print]

PMID:
29788107
2.

Differential microRNA expression profiles between young and old lung adenocarcinoma patients.

Giordano M, Boldrini L, Servadio A, Niccoli C, Melfi F, Lucchi M, Mussi A, Fontanini G.

Am J Transl Res. 2018 Mar 15;10(3):892-900. eCollection 2018.

3.

The role of intracavitary therapies in the treatment of malignant pleural mesothelioma.

Bertoglio P, Aprile V, Ambrogi MC, Mussi A, Lucchi M.

J Thorac Dis. 2018 Jan;10(Suppl 2):S293-S297. doi: 10.21037/jtd.2017.10.165. Review.

4.
5.

The everlasting story of malignant pleural mesothelioma: where do we stand?

Lucchi M, Mussi A, Bertolaccini L, Crisci R.

J Thorac Dis. 2018 Jan;10(Suppl 2):S192-S193. doi: 10.21037/jtd.2018.01.42. No abstract available.

6.

Presence and inter-individual variability of carboxylesterases (CES1 and CES2) in human lung.

Gabriele M, Puccini P, Lucchi M, Vizziello A, Gervasi PG, Longo V.

Biochem Pharmacol. 2018 Apr;150:64-71. doi: 10.1016/j.bcp.2018.01.028. Epub 2018 Feb 3.

PMID:
29407485
7.

Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10-year experience.

Ambrogi MC, Bertoglio P, Aprile V, Chella A, Korasidis S, Fontanini G, Fanucchi O, Lucchi M, Mussi A.

J Thorac Cardiovasc Surg. 2018 Apr;155(4):1857-1866.e2. doi: 10.1016/j.jtcvs.2017.10.070. Epub 2017 Nov 1.

PMID:
29191688
8.

Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma.

Boldrini L, Giordano M, Niccoli C, Melfi F, Lucchi M, Mussi A, Fontanini G.

Cancer Cell Int. 2017 Nov 17;17:105. doi: 10.1186/s12935-017-0474-y. eCollection 2017.

9.

The thymidylate synthase enhancer region (TSER) polymorphism increases the risk of thymic lymphoid hyperplasia in patients with Myasthenia Gravis.

Lopomo A, Ricciardi R, De Rosa A, Guida M, Maestri M, Lucchi M, Melfi F, Mussi A, Migliore L, Coppedè F.

Gene. 2018 Feb 5;642:376-380. doi: 10.1016/j.gene.2017.11.055. Epub 2017 Nov 21.

PMID:
29162511
10.

Is left upper lobectomy always worthwhile for early stage lung cancer? A comparison between left upper lobectomy, trisegmentectomy, and lingulectomy.

Aprile V, Bertoglio P, Dini P, Palmiero G, Mussi A, Ambrogi MC, Lucchi M.

J Surg Oncol. 2018 Mar;117(4):618-624. doi: 10.1002/jso.24884. Epub 2017 Oct 19.

PMID:
29049856
11.

New Keywords in the Treatment of Malignant Pleural Mesothelioma.

Bertoglio P, Lucchi M, Mussi A.

Ann Thorac Surg. 2017 Oct;104(4):1434. doi: 10.1016/j.athoracsur.2016.12.007. No abstract available.

PMID:
28935312
12.

Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.

De Santi C, Melaiu O, Bonotti A, Cascione L, Di Leva G, Foddis R, Cristaudo A, Lucchi M, Mora M, Truini A, Tironi A, Murer B, Boldorini R, Cipollini M, Gemignani F, Gasparini P, Mutti L, Landi S.

Sci Rep. 2017 Jun 9;7(1):3140. doi: 10.1038/s41598-017-02694-0.

13.

Single lymph node metastasis 10 years after radical resection of a thymoma.

Bertoglio P, Lucchi M, Aprile V, Alì G, Mussi A.

J Thorac Cardiovasc Surg. 2017 Jul;154(1):e11-e13. doi: 10.1016/j.jtcvs.2017.03.036. Epub 2017 Mar 19. No abstract available.

PMID:
28412120
14.

Prognostic role of TPL2 in early‑stage non‑small cell lung cancer.

Boldrini L, Giordano M, Servadio A, Niccoli C, Bertoglio P, Lucchi M, Melfi F, Mussi A, Fontanini G.

Mol Med Rep. 2017 Jun;15(6):3451-3458. doi: 10.3892/mmr.2017.6430. Epub 2017 Apr 3.

15.

Superficial vein thrombosis in non-varicose veins of the lower limbs and thrombophilia.

Lucchi G, Bilancini S, Tucci S, Lucchi M.

Phlebology. 2018 May;33(4):278-281. doi: 10.1177/0268355517690643. Epub 2017 Jan 29.

PMID:
28134019
16.

Gene-Specific Methylation Analysis in Thymomas of Patients with Myasthenia Gravis.

Lopomo A, Ricciardi R, Maestri M, De Rosa A, Melfi F, Lucchi M, Mussi A, Coppedè F, Migliore L.

Int J Mol Sci. 2016 Dec 16;17(12). pii: E2121. doi: 10.3390/ijms17122121.

17.

Chest wall resection for mesothelioma recurrence after surgery.

Bertoglio P, Fanucchi O, Ricciardi S, Chella A, Lucchi M, Mussi A.

Asian Cardiovasc Thorac Ann. 2016 Nov;24(9):893-895. Epub 2016 Oct 9.

PMID:
27926466
18.

Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.

Bruno R, Alì G, Giannini R, Proietti A, Lucchi M, Chella A, Melfi F, Mussi A, Fontanini G.

Oncotarget. 2017 Jan 10;8(2):2758-2770. doi: 10.18632/oncotarget.13174.

19.

Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.

Bonotti A, Simonini S, Pantani E, Giusti L, Donadio E, Mazzoni MR, Chella A, Marconi L, Ambrosino N, Lucchi M, Mussi A, Cristaudo A, Foddis R.

Int J Biol Markers. 2017 Mar 2;32(1):e126-e131. doi: 10.5301/jbm.5000229.

PMID:
27646775
20.

EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center.

Giannini R, Lupi C, Sensi E, Alì G, Proietti A, Boldrini L, Servadio A, Giordano M, Macerola E, Bruno R, Borrelli N, Chella A, Melfi F, Lucchi M, Ribechini A, Vasile E, Cappuzzo F, Mussi A, Fontanini G.

Oncol Rep. 2016 Aug;36(2):1166-72. doi: 10.3892/or.2016.4874. Epub 2016 Jun 14.

PMID:
27373829
21.

210P: Digital gene expression profiling to separate malignant pleural mesothelioma from benign reactive mesothelial hyperplasia.

Bruno R, Alì G, Giannini R, Lucchi M, Melfi F, Mussi A, Fontanini G.

J Thorac Oncol. 2016 Apr;11(4 Suppl):S148. doi: 10.1016/S1556-0864(16)30317-3. Epub 2016 Apr 15. No abstract available.

22.

Comparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group.

Filosso PL, Yao X, Ruffini E, Ahmad U, Antonicelli A, Huang J, Guerrera F, Venuta F, van Raemdonck D, Travis W, Lucchi M, Rimner A, Thomas P, Weder W, Rocco G, Detterbeck F, Korst R.

Eur J Cardiothorac Surg. 2016 Oct;50(4):766-771. Epub 2016 Mar 31.

PMID:
27032473
23.

Endoscopic thymectomy: a neurologist's perspective.

Ricciardi R, Melfi F, Maestri M, De Rosa A, Petsa A, Lucchi M, Mussi A.

Ann Cardiothorac Surg. 2016 Jan;5(1):38-44. doi: 10.3978/j.issn.2225-319X.2015.12.02.

24.

Induction therapy followed by surgical resection in Stage-III thimic epithelial tumors: Long-term results from a multicentre analysis of 108 cases.

Cardillo G, Lucchi M, Marulli G, Infante M, Leuzzi G, Mussi A, Carleo F, Facciolo F, Voulaz E, Rea F, Rapicetta C, Lococo F.

Lung Cancer. 2016 Mar;93:88-94. doi: 10.1016/j.lungcan.2016.01.008. Epub 2016 Jan 19.

PMID:
26898620
25.

Does myasthenia gravis influence overall survival and cumulative incidence of recurrence in thymoma patients? A Retrospective clinicopathological multicentre analysis on 797 patients.

Filosso PL, Evangelista A, Ruffini E, Rendina EA, Margaritora S, Novellis P, Rena O, Casadio C, Andreetti C, Guerrera F, Lausi PO, Diso D, Mussi A, Venuta F, Oliaro A, Lucchi M.

Lung Cancer. 2015 Jun;88(3):338-43. doi: 10.1016/j.lungcan.2015.03.007. Epub 2015 Mar 14.

26.

Expression status of candidate genes in mesothelioma tissues and cell lines.

Melaiu O, Melissari E, Mutti L, Bracci E, De Santi C, Iofrida C, Di Russo M, Cristaudo A, Bonotti A, Cipollini M, Garritano SI, Foddis R, Lucchi M, Pellegrini S, Gemignani F, Landi S.

Mutat Res. 2015 Jan;771:6-12. doi: 10.1016/j.mrfmmm.2014.11.002. Epub 2014 Nov 13.

PMID:
25771974
27.

Surgical treatment of recurrent thymoma: is it worthwhile?†.

Marulli G, Margaritora S, Lucchi M, Cardillo G, Granone P, Mussi A, Carleo F, Perissinotto E, Rea F.

Eur J Cardiothorac Surg. 2016 Jan;49(1):327-32. doi: 10.1093/ejcts/ezv086. Epub 2015 Mar 8.

PMID:
25755187
28.

Wedge resection and radiofrequency ablation for stage I nonsmall cell lung cancer.

Ambrogi MC, Fanucchi O, Dini P, Melfi F, Davini F, Lucchi M, Massimetti G, Mussi A.

Eur Respir J. 2015 Apr;45(4):1089-97. doi: 10.1183/09031936.00188014. Epub 2015 Feb 19.

29.

Pleural recurrence of thymoma: surgical resection followed by hyperthermic intrathoracic perfusion chemotherapy†.

Ambrogi MC, Korasidis S, Lucchi M, Fanucchi O, Giarratana S, Melfi F, Mussi A.

Eur J Cardiothorac Surg. 2016 Jan;49(1):321-6. doi: 10.1093/ejcts/ezv039. Epub 2015 Feb 9.

PMID:
25666471
30.

Transcollation® technique in the thoracoscopic treatment of primary spontaneous pneumothorax.

Ambrogi MC, Zirafa CC, Davini F, Giarratana S, Lucchi M, Fanucchi O, Melfi F, Mussi A.

Interact Cardiovasc Thorac Surg. 2015 Apr;20(4):445-8. doi: 10.1093/icvts/ivu431. Epub 2014 Dec 26.

PMID:
25542404
31.

Thymic carcinoma outcomes and prognosis: results of an international analysis.

Ahmad U, Yao X, Detterbeck F, Huang J, Antonicelli A, Filosso PL, Ruffini E, Travis W, Jones DR, Zhan Y, Lucchi M, Rimner A.

J Thorac Cardiovasc Surg. 2015 Jan;149(1):95-100, 101.e1-2. doi: 10.1016/j.jtcvs.2014.09.124. Epub 2014 Oct 5. Erratum in: J Thorac Cardiovasc Surg. 2016 Apr;151(4):1220.

32.

Development of the international thymic malignancy interest group international database: an unprecedented resource for the study of a rare group of tumors.

Huang J, Ahmad U, Antonicelli A, Catlin AC, Fang W, Gomez D, Loehrer P, Lucchi M, Marom E, Nicholson A, Ruffini E, Travis W, Van Schil P, Wakelee H, Yao X, Detterbeck F; International Thymic Malignancy Interest Group International Database Committee and Contributors.

J Thorac Oncol. 2014 Oct;9(10):1573-8. doi: 10.1097/JTO.0000000000000269. Erratum in: J Thorac Oncol. 2014 Dec;9(12):1804.

33.

A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people.

Garritano S, De Santi C, Silvestri R, Melaiu O, Cipollini M, Barone E, Lucchi M, Barale R, Mutti L, Gemignani F, Bonotti A, Foddis R, Cristaudo A, Landi S.

J Thorac Oncol. 2014 Nov;9(11):1662-8. doi: 10.1097/JTO.0000000000000322.

34.

P2X7 mRNA expression in non-small cell lung cancer: MicroRNA regulation and prognostic value.

Boldrini L, Giordano M, Alì G, Melfi F, Romano G, Lucchi M, Fontanini G.

Oncol Lett. 2015 Jan;9(1):449-453. Epub 2014 Oct 15.

35.

The ITMIG/IASLC Thymic Epithelial Tumors Staging Project: A Proposed Lymph Node Map for Thymic Epithelial Tumors in the Forthcoming 8th Edition of the TNM Classification of Malignant Tumors.

Bhora FY, Chen DJ, Detterbeck FC, Asamura H, Falkson C, Filosso PL, Giaccone G, Huang J, Kim J, Kondo K, Lucchi M, Marino M, Marom EM, Nicholson AG, Okumura M, Ruffini E, Van Schil P; Staging and Prognostic Factors Committee; Advisory Boards.

J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S88-96. doi: 10.1097/JTO.0000000000000293.

36.

The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors.

Kondo K, Van Schil P, Detterbeck FC, Okumura M, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, Filosso PL, Giaccone G, Huang J, Kim J, Lucchi M, Marino M, Marom EM, Nicholson AG, Ruffini E; Staging and Prognostic Factors Committee; Members of the Advisory Boards; Participating Institutions of the Thymic Domain.

J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S81-7. doi: 10.1097/JTO.0000000000000291.

37.

The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the T Component for the forthcoming (8th) edition of the TNM classification of malignant tumors.

Nicholson AG, Detterbeck FC, Marino M, Kim J, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, Filosso PL, Giaccone G, Huang J, Kondo K, Lucchi M, Marom EM, Okumura M, Ruffini E, Van Schil P; Staging and Prognostic Factors Committee; Members of the Advisory Boards; Participating Institutions of the Thymic Domain.

J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S73-80. doi: 10.1097/JTO.0000000000000303.

38.

The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors.

Detterbeck FC, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, Filosso PL, Frazier AA, Giaccone G, Huang J, Kim J, Kondo K, Lucchi M, Marino M, Marom EM, Nicholson AG, Okumura M, Ruffini E, Van Schil P; Staging and Prognostic Factors Committee; Members of the Advisory Boards; Participating Institutions of the Thymic Domain.

J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S65-72. doi: 10.1097/JTO.0000000000000290.

39.

Outcome of primary neuroendocrine tumors of the thymus: a joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases.

Filosso PL, Yao X, Ahmad U, Zhan Y, Huang J, Ruffini E, Travis W, Lucchi M, Rimner A, Antonicelli A, Guerrera F, Detterbeck F; European Society of Thoracic Surgeons Thymic Group Steering Committee.

J Thorac Cardiovasc Surg. 2015 Jan;149(1):103-9.e2. doi: 10.1016/j.jtcvs.2014.08.061. Epub 2014 Sep 16.

40.

Does the World Health Organization histological classification predict outcomes after thymomectomy? Results of a multicentre study on 750 patients.

Guerrera F, Rendina EA, Venuta F, Margaritora S, Ciccone AM, Novellis P, Novero D, Anile M, Bora G, Rena O, Casadio C, Mussi A, Evangelista A, Ruffini E, Lucchi M, Filosso PL.

Eur J Cardiothorac Surg. 2015 Jul;48(1):48-54. doi: 10.1093/ejcts/ezu368. Epub 2014 Sep 21.

PMID:
25246487
41.

A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors.

Petrini I, Meltzer PS, Kim IK, Lucchi M, Park KS, Fontanini G, Gao J, Zucali PA, Calabrese F, Favaretto A, Rea F, Rodriguez-Canales J, Walker RL, Pineda M, Zhu YJ, Lau C, Killian KJ, Bilke S, Voeller D, Dakshanamurthy S, Wang Y, Giaccone G.

Nat Genet. 2014 Aug;46(8):844-9. doi: 10.1038/ng.3016. Epub 2014 Jun 29.

42.

ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.

Alì G, Proietti A, Pelliccioni S, Niccoli C, Lupi C, Sensi E, Giannini R, Borrelli N, Menghi M, Chella A, Ribechini A, Cappuzzo F, Melfi F, Lucchi M, Mussi A, Fontanini G.

Arch Pathol Lab Med. 2014 Nov;138(11):1449-58. doi: 10.5858/arpa.2013-0388-OA. Epub 2014 Jun 2.

PMID:
24885803
43.

Robotic lobectomy for lung cancer: evolution in technique and technology.

Melfi FM, Fanucchi O, Davini F, Romano G, Lucchi M, Dini P, Ambrogi MC, Mussi A.

Eur J Cardiothorac Surg. 2014 Oct;46(4):626-30; discussion 630-1. doi: 10.1093/ejcts/ezu079. Epub 2014 Mar 9.

PMID:
24616391
44.

The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies.

Detterbeck FC, Asamura H, Crowley J, Falkson C, Giaccone G, Giroux D, Huang J, Kim J, Kondo K, Lucchi M, Marino M, Marom EM, Nicholson A, Okumura M, Ruffini E, van Schil P, Stratton K; Staging and Prognostic Factors Committee; Members of the Advisory Boards; Participating Institutions of the Thymic Domain.

J Thorac Oncol. 2013 Dec;8(12):1467-73. doi: 10.1097/JTO.0000000000000017.

45.

Historical perspectives: The evolution of the thymic epithelial tumors staging system.

Filosso PL, Ruffini E, Lausi PO, Lucchi M, Oliaro A, Detterbeck F.

Lung Cancer. 2014 Feb;83(2):126-32. doi: 10.1016/j.lungcan.2013.09.013. Epub 2013 Oct 15. Review.

PMID:
24377980
46.

Association of the DNMT3B -579G>T polymorphism with risk of thymomas in patients with myasthenia gravis.

Coppedè F, Ricciardi R, Denaro M, De Rosa A, Provenzano C, Bartoccioni E, Baggiani A, Lucchi M, Mussi A, Migliore L.

PLoS One. 2013 Nov 19;8(11):e80846. doi: 10.1371/journal.pone.0080846. eCollection 2013.

47.

Histo-cytological diagnostic accuracy in lung cancer.

Proietti A, Boldrini L, Alì G, Servadio A, Lupi C, Sensi E, Miccoli M, Ribechini A, Chella A, Lucchi M, Leocata P, Mussi A, Fontanini G.

Cytopathology. 2014 Dec;25(6):404-11. doi: 10.1111/cyt.12117. Epub 2013 Nov 20.

PMID:
24251636
48.

Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.

Alì G, Borrelli N, Riccardo G, Proietti A, Pelliccioni S, Niccoli C, Boldrini L, Lucchi M, Mussi A, Fontanini G.

J Thorac Oncol. 2013 Nov;8(11):1389-95. doi: 10.1097/JTO.0b013e3182a59f45.

49.

KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung.

Borrelli N, Giannini R, Proietti A, Alì G, Pelliccioni S, Niccoli C, Lucchi M, Melfi F, Mussi A, Basolo F, Fontanini G.

Lung Cancer. 2013 Sep;81(3):377-81. doi: 10.1016/j.lungcan.2013.06.026. Epub 2013 Jul 25.

PMID:
23891510
50.

Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features.

Capodanno A, Boldrini L, Proietti A, Alì G, Pelliccioni S, Niccoli C, D'Incecco A, Cappuzzo F, Chella A, Lucchi M, Mussi A, Fontanini G.

Int J Oncol. 2013 Sep;43(3):765-74. doi: 10.3892/ijo.2013.2003. Epub 2013 Jul 2.

PMID:
23820752

Supplemental Content

Loading ...
Support Center